• Jupiter Neurosciences entered a term sheet to acquire exclusive, perpetual U.S. licensing rights to PharmAla Biotech’s ALA-002, a next-generation MDMA drug candidate.
• The deal values the upfront consideration at USD 3.33 million, split between USD 1.5 million in cash and USD 1.83 million in common stock, with additional development milestones and single-digit royalties.
• ALA-002 is a patented, non-racemic MDMA formulation that the FDA has recognized as a Novel Chemical Entity, with the companies citing improved cardiovascular safety and reduced abuse liability versus racemic MDMA.
• Jupiter agreed to place USD 600,000 into escrow on signing, credited against the upfront cash payment at closing.
• The parties target signing definitive agreements within 90 days, subject to due diligence and customary approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200738PRIMZONEFULLFEED9723854) on May 20, 2026, and is solely responsible for the information contained therein.